BACKGROUND: Patients with allergic asthma have exacerbations which are frequently caused by rhinovirus infection. The antiviral tryptophan-catabolising enzyme indoleamine 2,3-dioxygenase (IDO) is induced by interferon-γ and suppressed by Th2 mediators interleukin (IL)-4 and IL-13. We hypothesised that local IDO activity after viral airway infection is lower in patients with allergic asthma than in healthy controls. OBJECTIVE: To determine whether IDO activity differs between patients with allergic asthma and healthy individuals before and after rhinovirus infection. METHODS: Healthy individuals and patients with allergic asthma were experimentally infected with low-dose (10 TCID50) rhinovirus 16. Blood, bronchoalveolar lavage fluid and exhaled breath condensate (for mass spectrometry by UPLC-MS/MS) were obtained before and after rhinovirus challenge. RESULTS: IDO activity was not induced by rhinovirus infection in either group, despite increases in cold scores. However, baseline pulmonary IDO activity was lower in patients with allergic asthma than in healthy individuals. In contrast, systemic tryptophan and its catabolites were markedly higher in patients with allergic asthma. Moreover, systemic quinolinic acid and tryptophan were associated with eosinophil cationic protein (r=0.43 and r=0.78, respectively) and eosinophils (r=0.38 and r=0.58, respectively) in bronchoalveolar lavage fluid and peak asthma symptom scores after rhinovirus challenge (r=0.53 and r=0.64, respectively). CONCLUSIONS: Rhinovirus infection by itself induces no IDO activity, but the reduced pulmonary IDO activity in patients with allergic asthma at baseline may underlie a reduced control of viral infections. Notably, the enhanced systemic catabolism of tryptophan in patients with allergic asthma was strongly related to the outcome of rhinovirus challenge in asthma and may serve as a prognostic factor.
BACKGROUND:Patients with allergic asthma have exacerbations which are frequently caused by rhinovirus infection. The antiviral tryptophan-catabolising enzyme indoleamine 2,3-dioxygenase (IDO) is induced by interferon-γ and suppressed by Th2 mediators interleukin (IL)-4 and IL-13. We hypothesised that local IDO activity after viral airway infection is lower in patients with allergic asthma than in healthy controls. OBJECTIVE: To determine whether IDO activity differs between patients with allergic asthma and healthy individuals before and after rhinovirus infection. METHODS: Healthy individuals and patients with allergic asthma were experimentally infected with low-dose (10 TCID50) rhinovirus 16. Blood, bronchoalveolar lavage fluid and exhaled breath condensate (for mass spectrometry by UPLC-MS/MS) were obtained before and after rhinovirus challenge. RESULTS:IDO activity was not induced by rhinovirus infection in either group, despite increases in cold scores. However, baseline pulmonary IDO activity was lower in patients with allergic asthma than in healthy individuals. In contrast, systemic tryptophan and its catabolites were markedly higher in patients with allergic asthma. Moreover, systemic quinolinic acid and tryptophan were associated with eosinophil cationic protein (r=0.43 and r=0.78, respectively) and eosinophils (r=0.38 and r=0.58, respectively) in bronchoalveolar lavage fluid and peak asthma symptom scores after rhinovirus challenge (r=0.53 and r=0.64, respectively). CONCLUSIONS:Rhinovirus infection by itself induces no IDO activity, but the reduced pulmonary IDO activity in patients with allergic asthma at baseline may underlie a reduced control of viral infections. Notably, the enhanced systemic catabolism of tryptophan in patients with allergic asthma was strongly related to the outcome of rhinovirus challenge in asthma and may serve as a prognostic factor.
Authors: Maria C Magnus; Øystein Karlstad; Øivind Midtun; Siri E Håberg; Gro Tunheim; Christine L Parr; Per Nafstad; Stephanie J London; Roy M Nilsen; Per M Ueland; Wenche Nystad Journal: J Allergy Clin Immunol Date: 2016-04-20 Impact factor: 10.793
Authors: Johanna M Gostner; Katrin Becker; Heinz Kofler; Barbara Strasser; Dietmar Fuchs Journal: Int Arch Allergy Immunol Date: 2016-05-04 Impact factor: 2.749
Authors: Christof J Majoor; Marianne A van de Pol; Pieter Willem Kamphuisen; Joost C M Meijers; Richard Molenkamp; Katja C Wolthers; Tom van der Poll; Rienk Nieuwland; Sebastian L Johnston; Peter J Sterk; Elisabeth H D Bel; Rene Lutter; Koenraad F van der Sluijs Journal: Respir Res Date: 2014-02-07
Authors: J J Hofstra; S Matamoros; M A van de Pol; B de Wever; M W Tanck; H Wendt-Knol; M Deijs; L van der Hoek; K C Wolthers; R Molenkamp; C E Visser; P J Sterk; R Lutter; M D de Jong Journal: BMC Infect Dis Date: 2015-08-14 Impact factor: 3.090
Authors: Alfred M Del Vecchio; Patrick J Branigan; Elliot S Barnathan; Susan K Flavin; Philip E Silkoff; Ronald B Turner Journal: Pulm Pharmacol Ther Date: 2014-11-13 Impact factor: 3.410